Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1999 1
2000 1
2001 1
2003 1
2004 1
2005 4
2006 2
2007 7
2008 11
2009 12
2010 5
2011 4
2012 6
2013 8
2014 4
2015 3
2016 4
2017 5
2018 3
2019 2
2020 1
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Among authors: piccart gebhart mj. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
Stemming resistance to HER-2 targeted therapy.
Bedard PL, Cardoso F, Piccart-Gebhart MJ. Bedard PL, et al. Among authors: piccart gebhart mj. J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):55-66. doi: 10.1007/s10911-009-9116-x. Epub 2009 Mar 4. J Mammary Gland Biol Neoplasia. 2009. PMID: 19259796 Review.
New tools for assessing breast cancer recurrence.
Dinh P, Cardoso F, Sotiriou C, Piccart-Gebhart MJ. Dinh P, et al. Among authors: piccart gebhart mj. Cancer Treat Res. 2008;141:99-118. doi: 10.1007/978-0-387-73161-2_7. Cancer Treat Res. 2008. PMID: 18274085 Review. No abstract available.
Pertuzumab: new hope for patients with HER2-positive breast cancer.
Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ. Capelan M, et al. Among authors: piccart gebhart mj. Ann Oncol. 2013 Feb;24(2):273-282. doi: 10.1093/annonc/mds328. Epub 2012 Aug 21. Ann Oncol. 2013. PMID: 22910839 Free article. Review.
Targeted therapies in breast cancer: are heart and vessels also being targeted?
Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Criscitiello C, et al. Among authors: piccart gebhart mj. Breast Cancer Res. 2012 Jun 19;14(3):209. doi: 10.1186/bcr3142. Breast Cancer Res. 2012. PMID: 22713170 Free PMC article. Review.
76 results